HomeAI · summaries
Storia in 8 fonti
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea,…
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential…
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
